Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

(2012) Linda Villard et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Radiotherapy with Radiolabeled Somatostatin Analogs

(2011) Guillaume Nicolas et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dosimetry in molecular nuclear therapy

(2011) Roel Wierts et al.   METHODS

Dosimetric Effectiveness of Targeted Radionuclide Therapy Based on a Pharmacokinetic Landscape

(2010) Joseph J. Grudzinski et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study

(2009) J. B. Cwikla et al.   ANNALS OF ONCOLOGY

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC

(2009) Maribel L. Sierra et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY

MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy

(2008) B. W. Wessels et al.   JOURNAL OF NUCLEAR MEDICINE